{
    "clinical_study": {
        "@rank": "30277", 
        "acronym": "CMAP", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients administrate Chiglitazar 32mg once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients administrate Chiglitazar 48mg once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare\n      with placebo."
        }, 
        "brief_title": "Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The efficacy and safety will be compared between Chiglitazar and placebo after treatment of\n      24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);\n\n          2. HbA1c\u2265 7.5% and \u2264 10.0% after control of diet and exercises;\n\n          3. Male and female,age between 18 and 70 years;\n\n          4. BMI between 18.5-35kg/m2;\n\n          5. Willing to be assigned to any treatment arm and sign inform consent.\n\n        Exclusion Criteria:\n\n          1. Type 1 diabetes;\n\n          2. Treated by oral or injective antidiabetic drug before screening, including insulin\n             and herb;\n\n          3. Fasting plasma glucose > 13.3 mmol/L (240 mg/dL);\n\n          4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3\n             optimally dosed antihypertensive medications (including diuretic) of different\n             classes,or blood pressure is controlled to below the goal by at least 4 different\n             classes of drugs];\n\n          5. Plasma triglyceride > 500 mg/dL (5.65 mmol/L);\n\n          6. Is treating by fibrates;\n\n          7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic\n             acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic\n             nephropathy and diabetic neuropathy;\n\n          8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past\n             6 months;\n\n          9. History of myocardial infarction or had conducted coronary angioplasty or coronary\n             artery bypass graft surgery;\n\n         10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy\n             indicated by ECG;\n\n         11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase\n             or alanine aminotransferase > 2.5 fold of the upper limit of the normal range;\n\n         12. Kidney diseases or serum creatinine exceed the normal range: male > 133 \u03bcmol/L or\n             female >108 \u03bcmol/L;\n\n         13. Had malignancy in the past 5 years, not including basal cell carcinoma;\n\n         14. Had or is currently receiving treatment that can alter blood glucose metabolism,\n             including but not limited to diuretic,hormone (corticotropin or steroids),beta\n             blockers;\n\n         15. Have the diseases that can alter blood glucose metabolism, including but not limited\n             to active hepatitis, hyperthyroidism,or adrenal tumors;\n\n         16. Edema with unknown reason;\n\n         17. Alcohol or drug addiction;\n\n         18. Had participated other drugs' clinical trials in the 3 months before screening;\n\n         19. Pregnant or lactic women; or women of childbearing age who are not able to or is not\n             willing to conduct contraception;\n\n         20. Any condition that make investigator consider the subject is not suitable to\n             participate the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "534", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121717", 
            "org_study_id": "CGZ301"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3"
                ], 
                "description": "Take orally", 
                "intervention_name": "Chiglitazar", 
                "intervention_type": "Drug", 
                "other_name": "CS038"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "Take orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Plb"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Chiglitazar,diabetes,type 2 diabetes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100044"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Linong Ji, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100101"
                    }, 
                    "name": "The 306th Hospital of PLA"
                }, 
                "investigator": {
                    "last_name": "Yanjun Liu, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200032"
                    }, 
                    "name": "Zhongshan Hospital Fudan University"
                }, 
                "investigator": {
                    "last_name": "Xin Gao, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial", 
        "overall_contact": {
            "email": "zhangqian@chipscreen.com", 
            "last_name": "Qian Zhang"
        }, 
        "overall_official": {
            "affiliation": "Peking University People's Hospital", 
            "last_name": "Linong Ji, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c from baseline after 24 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in HbA1c from baseline for patients with a baseline HbA1c >=8.5%", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Change in HbA1c from baseline in patients with a baseline HbA1c < 8.5%", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Change in HbA1c from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in HbA1c from baseline", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Percentage of patients that attained target HbA1c <7.0%", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients whose HbA1c lowered by at least 0.5%", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Change in fasting plasma glucose from baseline", 
                "safety_issue": "No", 
                "time_frame": "12,24 and 52 weeks"
            }, 
            {
                "measure": "Change in 2-h postprandial glucose (2hPPG) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in total cholesterol (TC) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in triglyceride from baseline", 
                "safety_issue": "No", 
                "time_frame": "12,24 and 52 weeks"
            }, 
            {
                "measure": "Change in high density lipoprotein cholesterol (HDL-C)from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in low density proprotein cholesterol (LDL-C) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in free fatty acid (FFA) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in fasting plasma insulin from baseline", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "12, 24 and 52 weeks"
            }, 
            {
                "measure": "Change in blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients who use rescue therapy", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Chipscreen Biosciences, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chipscreen Biosciences, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}